Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
The agency approved eight oncology products over the month.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Varegacestat’s pivotal study reads out imminently.
The pivotal Harmoni-GI3 study has started enrolling patients.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
